Russell J. Schilder, MD
Director, Drug Development, Sarah Cannon Research Institute at Sidney Kimmel Cancer Center
Dr. Schilder joined Sarah Cannon Research Institute at Sidney Kimmel Cancer Center in 2018 when the two organizations announced a collaboration to advance clinical research through an expanded early phase drug development program. In his role as director of the Early Drug Development Program, he oversees all Phase I trials involving two or more cancer types at Sidney Kimmel Cancer Center. Schilder also supervises other early drug development efforts, such as Phase 0 and basket trials involving multiple kinds of cancers.
Dr. Schilder received a Bachelor of Arts from Rutgers University, his medical degree and Master of Science from University of Miami, and completed his internal medicine residency at Temple University Hospital and fellowship in hematology-oncology at Temple University Hospital/Fox Chase Cancer Center.
Prior to joining Sarah Cannon Research Institute at Sidney Kimmel Cancer Center, he was the chief of Gynecologic Medical Oncology at Fox Chase Cancer Center. Schilder is board certified in internal medicine, hematology and medical oncology.